Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia

Yogaparan, Thirumagal; Panju, Abbas H.; Minden, Mark D.; Brandwein, Joseph; Mohamedali, Hassanabbas Z.; Alibhai, Shabbir M.H.

doi:10.1016/j.leukres.2008.12.008

Cited by 39 publications

(62 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many patients prefer to make their treatment decisions after discussing their oncologists’ opinions, 40% preferred that their oncologists make the treatment decisions. Yogaparan and colleagues also reported similar findings in a study of 31 patients with AML . Interestingly, studies have shown that most patients with advanced solid tumors prefer to make their own treatment decisions .…”

Section: Discussionmentioning

confidence: 55%

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

et al. 2018

View full text Add to dashboard Cite

Older patients with acute myeloid leukemia (AML) are confronted with challenging decisions regarding treatment with "intensive" chemotherapy that carries significant toxicity for a small chance of a cure versus "nonintensive" chemotherapy to control the disease, but with fewer side effects. A clear understanding of the likely outcome and risks of the various treatment strategies is essential for these patients to make informed decisions about their care. This article reports that older patients with AML overestimate both the risks and benefits of treatment and have substantial misperceptions about their prognosis. Interventions to enhance patients' understanding of their prognosis and treatment risk are needed.

show abstract

Section: Discussionmentioning

confidence: 55%

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For information needs, our results for the older age group paralleled those found by Yogaparan et al, who studied information needs in AML patients over 50 years of age. 6 Both studies found that older patients prefer to play passive decision-making roles and have high levels of trust in their physician. There are no published data on information needs in younger patients with AML.…”

Section: Discussionmentioning

confidence: 99%

“…The questionnaires included single-item global fatigue (from the Edmonton Symptom Assessment Scale 7 ), global health, and global quality of life scales (from the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 scale 8 ), the Control Preferences Scale (CPS), 9 the Decisional Regret scale, 10 the Satisfaction with Decision scale (SWD), 11 the Beck Depression Inventory (BDI), 12 and questions regarding the patient's information needs. 6 We briefly describe each of the measures below. The Edmonton Symptom Assessment Scale is a series of single-item 10-point numerical scales, each of which is validated and commonly used in patients with cancer.…”

Section: Data Collectionmentioning

confidence: 99%

“…5 Another cross-sectional study on newly diagnosed AML patients over the age of 50, done by our group, found that the majority of patients preferred to play a passive or collaborative role in treatment decision making, felt that doctors were honest and spent the right amount of time with them, and tended to overestimate their prognosis. 6 However, no similar studies have compared the needs and preferences of older versus younger adults. As such, it is important to further explore this decision-making process, and determine if the aforementioned issues are germane to all adult patients with AML or to only older patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Information needs, decisional regret and satisfaction of older and younger adults with acute myeloid leukemia

Mohamedali

Breunis

Panju

et al. 2010

Journal of Geriatric Oncology

Self Cite

View full text Add to dashboard Cite

“…Surveys of newly diagnosed patients with AML have demonstrated that the majority of individuals do not recall being offered more than one treatment option and grossly overestimate their long-term prognosis and chance for cure, although the treating physicians clearly documented discussion of these issues in the patients' medical charts. 19,52 A mutual understanding between the patient, his/her family members, and the treating oncologist early in the treatment process that the disease will eventually be life-ending may make it easier to hold subsequent conversations on topics such as health care proxies, do not resuscitate/do not intubate directives, and end-of-life care when the time comes.…”

Section: Communicating Treatment Outcomes To Older Aml Patientsmentioning

confidence: 99%

Treating acute myeloid leukemia in older adults

Wang

2014

Hematology

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a disease of older adults, with a median age of 67 years at presentation. In the past, only a third of older patients (defined as individuals older than 60-65 years of age) with AML received definitive therapy for their disease due to concerns about their overall fitness and potential treatment-related mortality. However, compelling epidemiological data have shown unequivocally that older AML patients up to 80 years old both tolerate and survive longer after therapy than their untreated counterparts. Current therapeutic options for elderly individuals with AML include intensive chemotherapy with a cytarabine and anthracycline backbone, hypomethylating agents (decitabine and azacitidine), low-dose cytarabine, investigational agents, and supportive care with hydroxyurea and transfusions. Over the last few years, there has been increasing debate regarding the appropriate therapeutic approach to take in older adults given the diversity of the geriatric patient population and heterogeneous AML disease biology. This article discusses how performance status, comorbidities, disease characteristics, quality of life concerns, and long-term treatment goals affect the selection of appropriate therapy for older adults with AML. Risks and benefits of each treatment approach based on the most recent medical literature are discussed. Finally, a treatment algorithm summarizing these data and incorporating geriatric assessment and molecular and cytogenetic markers predictive of therapeutic response is proposed to aid in the clinical decision-making process. Learning Objective• To identify appropriate therapeutic strategies for the older patient with AML, taking into consideration the patient's performance status, comorbidities, disease characteristics, and goals

show abstract

Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia

Cited by 39 publications

References 5 publications

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

Information needs, decisional regret and satisfaction of older and younger adults with acute myeloid leukemia

Treating acute myeloid leukemia in older adults

Contact Info

Product

Resources

About